⚠ Research and educational use only — not for human consumption. Nothing for sale, no dosing advice. PeptideCompare is non-profit and independent.
Compare free →
Suppliers 🛡 Quality & badges 📖 Encyclopedia 📰 Articles 🧪 Calculator
LONGEVITY TOPICS
⚡ NAD+ Precursors 🔑 Sirtuin Activators 🧹 Senolytics ♻️ Autophagy 🔋 Mitochondrial 🌡️ Hormesis
About FAQ Contact Policy
MONOGRAPH No. 123
TYPE
GLP-1 agonist
MW
4186.6 g/mol
CAS
141732-76-5
EU STATUS
EMA approved (Byetta/Bydureon)
WADA
Not prohibited
MIN PURITY
≥98% HPLC
⚖ GLP-1 & Weight

Exenatide — EU research guide.

Exenatide is the original GLP-1 receptor agonist, derived from a peptide found in Gila monster venom — the foundation compound that opened the entire incretin drug class now led by semaglutide and tirzepatide.

Last reviewed:

What is Exenatide?

Exenatide is a synthetic version of exendin-4, a GLP-1-receptor-activating peptide first isolated from Gila monster saliva. It slows gastric emptying, boosts glucose-dependent insulin release and reduces appetite, administered as Byetta (twice-daily) or Bydureon (once-weekly extended-release).

What does the research show?

Approved by the FDA in 2005 and the EMA shortly after, exenatide has decades of outcomes data in type 2 diabetes, including the EXSCEL cardiovascular-safety trial. Its weight-loss effect is modest compared with newer analogues, which is why it has been largely superseded by liraglutide, semaglutide and tirzepatide.

EU legal status

EMA-approved prescription medicine for type 2 diabetes; also available as a research-grade peptide from RUO suppliers.

Superseded by longer-acting, more effective GLP-1 analogues for most indications; still prescribed in some diabetes protocols.
✓ For the current-generation GLP-1 compounds, PeptideCompare tracks semaglutide and tirzepatide from EU research vendors with COA documentation.

Molecular information

Molecular formula
C184H282N50O60S
Molecular weight
4186.6 g/mol
CAS number
141732-76-5

Pharmacokinetics

Route
Subcutaneous
Half-life (t½)
≈2.4 h
Tmax
≈2.1 h
Source: FDA Byetta label
Research context only — not dosing guidance.

GLP-1 compounds across EU suppliers

COA-verified EU vendors · Updated monthly

Frequently asked questions

What is Exenatide?

Exenatide is a synthetic version of exendin-4, a GLP-1-receptor-activating peptide first isolated from Gila monster saliva. It slows gastric emptying, boosts glucose-dependent insulin release and reduces appetite.

What does the research show?

Approved by the FDA in 2005 and the EMA shortly after, it has decades of type 2 diabetes outcomes data including the EXSCEL cardiovascular-safety trial, though its weight-loss effect is modest compared with newer analogs.

Why has exenatide been largely superseded?

Its weight-loss effect is modest compared with newer analogs, which is why it has been largely replaced by liraglutide, semaglutide and tirzepatide.

What is the difference between Byetta and Bydureon?

Byetta is the twice-daily form and Bydureon is the once-weekly extended-release form of exenatide.

Is exenatide legal in the EU?

It is an EMA-approved prescription medicine for type 2 diabetes and is also available as a research-grade peptide.

Is exenatide banned in sport?

No. It is not prohibited by WADA.

Related guides

PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
What does COA Verified mean? Most tested supplier? Is this legal here?
Navigation assistant · no medical advice